Janssen Sciences Ireland Uc competitive analysis

Explore patent oppositions filed by Janssen Sciences Ireland Uc against competitors, revealing strategic technology disputes and market positioning.

Last updated on: Sep 17, 2026
Patent NumberTitleApplicantOpposition Date
Methods And Compositions For The Treatment Of Persistent Infections And Cancer By Inhibiting The Programmed Cell Death 1 (Pd-1)PathwayDANA FARBER CANCER INSTITUTESep 13, 2018
Solid Pharmaceutical Dosage Form Comprising An Hiv Protease Inhibitor Solid DispersionABBOTT LABORATORIESJun 21, 2017

Explore Janssen Sciences Ireland Uc's recently opposed patents, revealing key competitive challenges and strategic patent disputes in the industry. Track oppositions filed by competitors to understand technology battlegrounds and assess potential risks.

Last updated on: Sep 17, 2026
Patent NumberPublication DateTitleTotal Oppositions
Mar 1, 2023Combinations Of A Pyrimidine Containing Nnrti With Rt Inhibitors1
Dec 1, 2021Therapeutic Compositions Comprising Rilpivirine Hcl And Tenofovir Disoproxil Fumarate2
Jan 24, 2018Aqueous Suspensions Of Tmc2781
Jul 12, 2017Pseudopolymorphic Forms Of A Hiv Protease Inhibitor1

Latest PTAB cases involving Janssen Sciences Ireland Uc

Discover the latest PTAB cases involving Janssen Sciences Ireland Uc, highlighting their recent legal challenges and patent disputes.

Last updated on: Sep 17, 2026
Proceeding NumberFiling DatePetitionerRespondentStatus

Get alerts for PTAB Cases involving Janssen Sciences Ireland Uc

IPR2015-01030Apr 9, 2015LUPINJANSSEN SCIENCES IRELAND UCInstitution Denied

Peer Comparison New

IP litigation analysis comparing Janssen Sciences Ireland Uc with top 3 competitors. Includes complete PTAB case data and opposition data from 2018 onwards.

Last updated on: Sep 17, 2026
CompanyOppositions FiledOppositions FacedPTAB Cases FiledPTAB Cases Faced
JANSSEN SCIENCES IRELAND UC25 - 1
LUPIN1115 -